Dry Eye Disease
Find information on Dry Eye Disease (DED), also known as Dry Eye Syndrome or Keratoconjunctivitis Sicca. This resource offers guidance on clinical documentation, medical coding, and healthcare best practices for diagnosing and managing dry eye. Learn about symptoms, diagnostic criteria, and treatment options for DED. Improve your understanding of Dry Eye Disease for accurate and efficient healthcare documentation and coding.
Insufficient tear production or excessive tear evaporation, causing eye dryness and irritation.
Burning, itching, redness, foreign body sensation, blurred vision, light sensitivity.
Primary care, ophthalmology, optometry clinics. Treatment includes artificial tears, lifestyle changes.
ICD-10 Code Families
Complete code families applicable to H04.123
When to use each related code
| Description | When to use |
|---|---|
| Dry eyes, insufficient lubrication. | Use for decreased tear production or excessive tear evaporation. Consider severity and etiology. |
| Inflamed cornea, often from infection. | Use for corneal inflammation, often with pain, redness, and discharge. Specify infectious agent if known. |
| Inflamed conjunctiva, various causes. | Use for conjunctival inflammation, with redness, itching, and discharge. Specify allergic, viral, etc. if known. |
Best-practice checklist
- ✓Dry eye symptoms: FB, grittiness, burning, etc.
- ✓Schirmer's test or tear breakup time results
- ✓Ocular surface assessment: redness, staining
- ✓Patient-reported DED impact on daily life
- ✓Treatment plan: artificial tears, other therapy
Common pitfalls to avoid
Coding dry eye without specifying severity (mild, moderate, severe) can lead to underpayment and inaccurate quality reporting.
Failing to code associated conditions like blepharitis, MGD, or Sjogren's Syndrome impacts reimbursement and care planning.
Incorrectly coding dry eye laterality (one eye vs. both eyes) affects billing accuracy and statistical analysis.
Best-practice tips
- 01Artificial tears: Use preservative-free drops.
- 02Warm compresses: Apply to eyelids for 5-10 minutes.
- 03Omega-3s: Incorporate into diet or take supplements.
- 04Avoid dry environments: Use a humidifier indoors.
- 05Blink regularly: Especially during prolonged screen time.
Step-by-step checklist
- 1
Confirm symptoms: dryness, grittiness, burning?
- 2
Evaluate tear film: Schirmer's, TBUT?
- 3
Assess ocular surface: redness, staining?
- 4
Rule out other causes: allergies, medications?
- 5
ICD-10 H04.12, H16.20: Document findings.
Ready-to-paste narrative
Patient presents with complaints consistent with dry eye disease (DED), also known as dry eye syndrome or keratoconjunctivitis sicca. Symptoms include ocular dryness, burning sensation, foreign body sensation, grittiness, and intermittent blurry vision. Patient reports increased discomfort in low-humidity environments, during prolonged computer use, and after extended reading. On examination, tear film breakup time (TBUT) is reduced, and corneal fluorescein staining reveals punctate epithelial erosions. Schirmer's test results indicate diminished tear production. Assessment suggests mild to moderate dry eye disease, likely contributing to the patient's reported ocular discomfort. The patient's medical history is significant for hypothyroidism, which may be a contributing factor. Current medications include levothyroxine. No known drug allergies. Diagnosis of dry eye disease is made based on patient symptoms, clinical findings, and diagnostic test results. Treatment plan includes artificial tears for symptomatic relief, education on proper eyelid hygiene including warm compresses and lid scrubs, and recommendations for environmental modifications such as increasing humidity. Patient advised to avoid prolonged screen time and take frequent breaks during visually demanding tasks. Follow-up scheduled in four weeks to assess response to treatment and consider additional therapeutic options such as punctal plugs if symptoms persist. ICD-10 code H04.123 (Unspecified keratoconjunctivitis sicca, moderate) assigned. This documentation supports medical necessity for the prescribed treatment and diagnostic testing.
Common questions and answers
What are the most effective diagnostic tests for differentiating aqueous deficient dry eye disease from evaporative dry eye disease in clinical practice?+
Accurately differentiating between aqueous deficient dry eye (ADDE) and evaporative dry eye (EDE) is crucial for targeted treatment. Schirmer's test, while a common initial screening tool, primarily assesses aqueous tear production and may not fully capture EDE. Tear film osmolarity measurement provides a more comprehensive assessment of tear stability and is considered a valuable marker for both ADDE and EDE. Additionally, meibography allows for visualization of meibomian gland morphology and function, aiding in the diagnosis of meibomian gland dysfunction (MGD), a major contributor to EDE. Other useful tests include tear break-up time (TBUT) and assessment of tear meniscus height. A combination of these diagnostic tests allows for a more nuanced understanding of the underlying cause of dry eye and facilitates personalized treatment strategies. Explore how integrating tear osmolarity and meibography into your dry eye assessment can improve patient outcomes.
How can I effectively manage dry eye disease in patients with concurrent systemic autoimmune conditions like Sjogren's syndrome, rheumatoid arthritis, or lupus?+
Managing dry eye disease (DED) in patients with systemic autoimmune conditions requires a comprehensive approach that addresses both the ocular surface inflammation and the underlying systemic disease. In conditions like Sjogren's syndrome, rheumatoid arthritis, and lupus, the autoimmune response can exacerbate DED, leading to more severe symptoms. Beyond artificial tears, consider implementing topical cyclosporine or lifitegrast to manage inflammation. Punctal plugs can help retain natural tears on the ocular surface, while warm compresses and lid hygiene can improve meibomian gland function, particularly in patients with evaporative dry eye. Close collaboration with the patient's rheumatologist is essential to ensure optimal management of the systemic condition and minimize its impact on ocular health. Learn more about the interplay between systemic autoimmune diseases and DED to develop effective, personalized treatment plans.
Beyond artificial tears, what are the latest therapeutic options for managing chronic dry eye disease, including new pharmaceutical agents and in-office procedures?+
While artificial tears provide symptomatic relief, chronic dry eye disease (DED) often necessitates more targeted therapies. Topical cyclosporine and lifitegrast, immunomodulatory agents, help manage ocular surface inflammation, a key driver of DED. In cases of meibomian gland dysfunction (MGD), intense pulsed light (IPL) therapy and thermal pulsation can improve gland function and tear film stability. Newer pharmaceutical agents, such as varenicline, are under investigation for their potential to improve tear production. Additionally, autologous serum tears, rich in growth factors and other beneficial components, offer a promising personalized approach for severe DED. Consider implementing advanced therapeutic options, like IPL and autologous serum tears, to address the underlying causes of chronic DED and enhance patient comfort.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.